Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial
Author(s) -
Shunichi Kimura,
Yoshinobu Kanda,
Masaki Iino,
Takahiro Fukuda,
Emiko Sakaida,
Tatsuo Oyake,
Hiroki Yamaguchi,
Shinichiro Fujiwara,
Yumi Jo,
Akinao Okamoto,
Hiroyuki Fujita,
Yasushi Takamatsu,
Yoshio Saburi,
Itaru Matsumura,
Jun Yamanouchi,
Souichi Shiratori,
Moritaka Gotoh,
Shingen Nakamura,
Kazuo Tamura
Publication year - 2020
Publication title -
international journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 89
eISSN - 1878-3511
pISSN - 1201-9712
DOI - 10.1016/j.ijid.2020.08.081
Subject(s) - micafungin , medicine , neutropenia , febrile neutropenia , hematopoietic stem cell transplantation , absolute neutrophil count , gastroenterology , transplantation , antifungal , chemotherapy , amphotericin b , dermatology
The D-index is defined as the area over the neutrophil curve during neutropenia. The CEDMIC trial confirmed the noninferiority of D-index-guided early antifungal therapy (DET) using micafungin to empirical antifungal therapy (EAT). In this study, we evaluated the efficacy and safety of micafungin in these settings.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom